- Home
- APPS vs PSNL Comparison
APPS vs PSNL Comparison
Compare APPS & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- PSNL
- Stock Information
- Founded
- APPS N/A
- PSNL 2011
- Country
- APPS United States
- PSNL United States
- Employees
- APPS N/A
- PSNL N/A
- Industry
- APPS Multi-Sector Companies
- PSNL Medical Specialities
- Sector
- APPS Miscellaneous
- PSNL Health Care
- Exchange
- APPS Nasdaq
- PSNL Nasdaq
- Market Cap
- APPS 562.7M
- PSNL 518.8M
- IPO Year
- APPS N/A
- PSNL 2019
- Fundamental
- Price
- APPS $6.83
- PSNL $8.68
- Analyst Decision
- APPS Buy
- PSNL Strong Buy
- Analyst Count
- APPS 3
- PSNL 4
- Target Price
- APPS $4.83
- PSNL $8.13
- AVG Volume (30 Days)
- APPS 3.4M
- PSNL 931.2K
- Earning Date
- APPS 11-05-2025
- PSNL 11-05-2025
- Dividend Yield
- APPS N/A
- PSNL N/A
- EPS Growth
- APPS N/A
- PSNL N/A
- EPS
- APPS N/A
- PSNL N/A
- Revenue
- APPS $503,443,000.00
- PSNL $80,317,000.00
- Revenue This Year
- APPS $10.64
- PSNL N/A
- Revenue Next Year
- APPS $11.24
- PSNL $29.83
- P/E Ratio
- APPS N/A
- PSNL N/A
- Revenue Growth
- APPS N/A
- PSNL 0.36
- 52 Week Low
- APPS $1.18
- PSNL $2.83
- 52 Week High
- APPS $7.77
- PSNL $8.68
- Technical
- Relative Strength Index (RSI)
- APPS 78.26
- PSNL 78.43
- Support Level
- APPS $6.10
- PSNL $5.86
- Resistance Level
- APPS $6.83
- PSNL $7.52
- Average True Range (ATR)
- APPS 0.39
- PSNL 0.35
- MACD
- APPS 0.16
- PSNL 0.15
- Stochastic Oscillator
- APPS 93.42
- PSNL 98.64
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.